Spero Therapeutics (SPRO) Revenue (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Revenue came in at $12.6 million in Q4 2025, up 24107.69% YoY from N/an in Q4 2024, and up 104800.0% on a QoQ basis from $12000.0 in Q1 2025.
Spero Therapeutics (SPRO) Revenue (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 10 years of Revenue data on file, last reported at $12.6 million in Q4 2025.
- Quarterly Revenue rose 24107.69% year-over-year to $12.6 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $12.6 million (up 21.91% YoY) and the FY2025 annual result came in at $12.6 million, up 3296.23% from the prior year.
- Revenue rose to $12.6 million in Q4 2025, from $12000.0 in the prior quarter.
- In the past five years, Revenue ranged from a high of $25.5 million in Q3 2023 to a low of -$29.3 million in Q4 2023.
- A 5-year average of $2.3 million and a median of $802000.0 in 2021 frame the typical range for Revenue.
- Annual changes were most pronounced in 2023 — Revenue plunged 274.82% — and 2025, when it surged 24107.69%.
- Tracing SPRO's Revenue over 5 years: stood at -$12.4 million in 2021, then surged by 234.83% to $16.8 million in 2022, then sank by 274.82% to -$29.3 million in 2023, then soared by 100.18% to $52000.0 in 2024, then surged by 24107.69% to $12.6 million in 2025.
- The last three Revenue figures came in at $12.6 million (Q4 2025), $12000.0 (Q1 2025), and $52000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.99 Bn | 132.14 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 86.80 Bn | 78.80 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 65.38 Bn | 60.19 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 60.70 Bn | 55.56 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 1.29 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 1.06 Bn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 425.49 Mn |
| 9 | Royalty Pharma | 27.21 Bn | 26.37 Bn | - | 674.14 Mn |
| 10 | Spero Therapeutics | 71.30 Mn | 20.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 258,000.00 |
| Dec 31, 2025 | 12.59 Mn |
| Mar 31, 2025 | 12,000.00 |
| Dec 31, 2024 | 52,000.00 |
| Sep 30, 2024 | 65,000.00 |
| Jun 30, 2024 | 10.20 Mn |
| Mar 31, 2024 | 140,000.00 |
| Dec 31, 2023 | -29.33 Mn |
| Sep 30, 2023 | 25.47 Mn |
| Jun 30, 2023 | 2.72 Mn |
| Mar 31, 2023 | 223,000.00 |
| Dec 31, 2022 | 16.78 Mn |
| Sep 30, 2022 | 1.08 Mn |
| Jun 30, 2022 | 896,000.00 |
| Mar 31, 2022 | 247,000.00 |
| Dec 31, 2021 | -12.44 Mn |
| Sep 30, 2021 | 708,000.00 |
| Jun 30, 2021 | 5.15 Mn |
| Mar 31, 2021 | 7.30 Mn |
| Sep 30, 2020 | 38,000.00 |